Home
TRDA
TRDA News

Latest Entrada Therapeutics Inc. (TRDA) News on June 2, 2025

Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU

Clinical Trials Arena

4 days ago

Entrada’s Phase I/II trial of DMD treatment authorised to begin in EU

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

GlobeNewswire

5 days ago

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

Simply Wall St.

22 days ago

Analysts Are Upgrading Entrada Therapeutics, Inc. (NASDAQ:TRDA) After Its Latest Results

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

Zacks

25 days ago

Entrada Therapeutics, Inc. (TRDA) Reports Q1 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports First Quarter 2025 Financial Results

GlobeNewswire

25 days ago

Entrada Therapeutics Reports First Quarter 2025 Financial Results

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Zacks

a month ago

Eton Pharmaceuticals, Inc. (ETON) Earnings Expected to Grow: What to Know Ahead of Q1 Release

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

BioPharma Dive

a month ago

Arvinas, Entrada cut staff; Merck builds US hub for Keytruda

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Zacks

a month ago

Analysts Estimate Entrada Therapeutics, Inc. (TRDA) to Report a Decline in Earnings: What to Look Out for

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Zacks

2 months ago

Ultragenyx (RARE) Soars 9.2%: Is Further Upside Left in the Stock?

Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment

Clinical Trials Arena

2 months ago

Entrada gains UK MHRA authorisation to start Phase I/II trial of DMD treatment

MT Newswires

2 months ago

Entrada Therapeutics Duchenne Muscular Dystrophy Investigational Treatment Study Gets Approval in UK

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

GlobeNewswire

2 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Simply Wall St.

3 months ago

Entrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen Next

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Zacks

3 months ago

Entrada Therapeutics, Inc. (TRDA) Surpasses Q4 Earnings and Revenue Estimates

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

3 months ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

Zacks

3 months ago

Biotech Stock Roundup: BLUE Down on Update, News From GILD, TRDA

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

BioPharma Dive

3 months ago

AstraZeneca’s next breast cancer drug; Madrigal’s accelerating MASH launch

FDA removes clinical hold on Entrada’s Duchenne therapy

Clinical Trials Arena

3 months ago

FDA removes clinical hold on Entrada’s Duchenne therapy

MT Newswires

3 months ago

Sector Update: Health Care Stocks Flat to Higher Pre-Bell Monday

MT Newswires

3 months ago

Entrada Therapeutics Says FDA Lifted Clinical Hold on ENTR-601-44; Shares Advance Premarket

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

GlobeNewswire

3 months ago

Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

Insider Monkey

4 months ago

Entrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In Now

Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment

Clinical Trials Arena

4 months ago

Entrada gets UK MHRA authorisation to begin Phase I/II trial of DMD treatment

MT Newswires

4 months ago

Entrada Therapeutics Gets UK Approval for Phase 1/2 Study of Duchenne Muscular Dystrophy Treatment

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

GlobeNewswire

4 months ago

Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy

Azenta Announces the Election of Dipal Doshi to its Board of Directors

PR Newswire

4 months ago

Azenta Announces the Election of Dipal Doshi to its Board of Directors

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Simply Wall St.

4 months ago

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Best Momentum Stocks to Buy for December 30th

Zacks

5 months ago

Best Momentum Stocks to Buy for December 30th

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

5 months ago

Entrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

TipRanks

6 months ago

Roth MKM starts ‘overlooked’ Entrada Therapeutics with Buy rating

MT Newswires

6 months ago

Roth Initiates Entrada Therapeutics at Buy

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why

Zacks

6 months ago

Entrada Therapeutics (TRDA) Is a Great Choice for 'Trend' Investors, Here's Why

MT Newswires

7 months ago

Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

7 months ago

Entrada Therapeutics Third Quarter 2024 Earnings: Beats Expectations

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

Zacks

7 months ago

Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

GlobeNewswire

7 months ago

Entrada Therapeutics Reports Third Quarter 2024 Financial Results

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

GlobeNewswire

8 months ago

Entrada Therapeutics Presents New Data Supporting its Expanding Duchenne Franchise at the 29th Annual Congress of the World Muscle Society

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

GlobeNewswire

8 months ago

Entrada Therapeutics Promotes Natarajan Sethuraman, PhD, to President of Research and Development

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

GlobeNewswire

9 months ago

Entrada Therapeutics Announces Recipients of Second Annual Diversity, Representation, Equity and Advocacy MatterS (DREAMS) Grant Program

Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically

Simply Wall St.

9 months ago

Forecast: Analysts Think Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Business Prospects Have Improved Drastically

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

Zacks

10 months ago

AstraZeneca (AZN) Imfinzi Combo Gets EU Nod for Uterine Cancer

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

Zacks

10 months ago

Evotec (EVO) Rises 12% on $75M Milestone Payment From BMY

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Zacks

10 months ago

Syros (SYRS) Falls 62% on Phase II Leukemia Study Termination

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

Zacks

10 months ago

Entrada Therapeutics, Inc. (TRDA) Tops Q2 Earnings and Revenue Estimates

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Entrada Therapeutics Reports Second Quarter 2024 Financial Results

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Zacks

10 months ago

Merck (MRK) to Buy Curon's Bispecific Antibody Drug for $1.3B

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Zacks

10 months ago

Pacira (PCRX) Plummets as US Court Deems Exparel Patent Invalid

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Zacks

10 months ago

Insmed (INSM) Lags on Q2 Earnings, Tops Sales, Reiterates View

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Zacks

10 months ago

Novavax (NVAX) Lags on Q2 Earnings & Sales, Cuts '24 Outlook

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Zacks

10 months ago

Iovance (IOVA) Q2 Earnings Beat, Stock Up on Upbeat Sales View

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Zacks

10 months ago

Allogene (ALLO) Posts Narrower Than Expected Loss in Q2

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Zacks

10 months ago

Sarepta (SRPT) Q2 Earnings Top Estimates, Sales Lag, View Weak

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Zacks

10 months ago

Madrigal (MDGL) Tops on Q2 Earnings, NASH Drug Drives Top Line

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?

Simply Wall St.

10 months ago

Is Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Recent Price Movement Underpinned By Its Weak Fundamentals?

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Zacks

10 months ago

Perrigo (PRGO) Beats on Q2 Earnings, Lags Sales, Cuts View

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

Zacks

10 months ago

Moderna (MRNA) Q2 Earnings Beat, Stock Down on Guidance Slash

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

Zacks

10 months ago

JAZZ Tops Q2 Earnings & Sales Estimates, Revises '24 View

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

Zacks

10 months ago

United Therapeutics (UTHR) Q2 Earnings Lag, Sales Top Estimates

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Zacks

10 months ago

Merck (MRK) Q2 Earnings & Sales Beat Estimates, Cuts '24 EPS View

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Zacks

10 months ago

Wall Street Analysts See a 25.73% Upside in Entrada Therapeutics (TRDA): Can the Stock Really Move This High?

Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?

Zacks

a year ago

Entrada Therapeutics (TRDA) Moves 10.4% Higher: Will This Strength Last?

Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Travere (TVTX): Can Its 8.8% Jump Turn into More Strength?

Best Momentum Stocks to Buy for July 9th

Zacks

a year ago

Best Momentum Stocks to Buy for July 9th

With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors

Simply Wall St.

a year ago

With 40% ownership, Entrada Therapeutics, Inc. (NASDAQ:TRDA) has piqued the interest of institutional investors

MT Newswires

a year ago

Entrada Therapeutics Signs Securities Purchase Agreement of 3.4 Million Common Shares in Registered Direct Offering

Entrada Therapeutics Announces $100 Million Registered Direct Offering

GlobeNewswire

a year ago

Entrada Therapeutics Announces $100 Million Registered Direct Offering

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

GlobeNewswire

a year ago

Entrada Therapeutics Reports Positive Preliminary Data in Healthy Volunteers from Phase 1 ENTR-601-44-101 Trial for Duchenne Muscular Dystrophy

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

a year ago

Entrada Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

Zacks

a year ago

Wall Street Analysts Think Entrada Therapeutics (TRDA) Could Surge 37.08%: Read This Before Placing a Bet

MT Newswires

a year ago

Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing

Argus Research

a year ago

Daily – Vickers Top Buyers & Sellers for 05/17/2024

Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)

GuruFocus.com

a year ago

Director Peter Kim Acquires 25,000 Shares of Entrada Therapeutics Inc (TRDA)

MT Newswires

a year ago

Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire

a year ago

Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Entrada Therapeutics First Quarter 2024 Earnings: Beats Expectations

Entrada Therapeutics Reports First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Entrada Therapeutics Reports First Quarter 2024 Financial Results

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

GuruFocus.com

a year ago

Director Peter Kim Acquires 9,048 Shares of Entrada Therapeutics Inc (TRDA)

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates

Simply Wall St.

a year ago

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Just Slashed This Year's Estimates

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

GuruFocus.com

a year ago

Entrada Therapeutics Inc (TRDA) Reports Solid Financial Position and Advancements in Clinical Trials

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

a year ago

Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Entrada Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Entrada Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Employers Holdings, Inc. Schedules Fourth Quarter and Full-Year 2023 Earnings Release and Conference Call

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks

TipRanks

a year ago

‘Time to Pull the Trigger,’ Says Oppenheimer About These 3 Stocks

American Couples Should Count on Needing At Least This Much Money For Retirement Each Month

SmartAsset

a year ago

American Couples Should Count on Needing At Least This Much Money For Retirement Each Month

Associated Press Finance

a year ago

Fair Isaac: Fiscal Q1 Earnings Snapshot

Hudson Pacific Properties Announces 2023 Dividend Tax Treatment

Business Wire

a year ago

Hudson Pacific Properties Announces 2023 Dividend Tax Treatment

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

Business Wire

a year ago

Amerant Reports Fourth Quarter 2023 and Full-Year 2023 Results

SpartanNash Implements New Food Traceability Program, Strengthening Safety and Transparency Throughout Its Global Supply Chain

PR Newswire

a year ago

SpartanNash Implements New Food Traceability Program, Strengthening Safety and Transparency Throughout Its Global Supply Chain

Olympic Steel Promotes Anthony G. Dominic to Vice President of Safety, Health and Environment

Business Wire

a year ago

Olympic Steel Promotes Anthony G. Dominic to Vice President of Safety, Health and Environment

Invesco Municipal Opportunity Trust's Dividend Analysis

GuruFocus.com

a year ago

Invesco Municipal Opportunity Trust's Dividend Analysis

ProPetro Announces Fourth Quarter 2023 Earnings Call

Business Wire

a year ago

ProPetro Announces Fourth Quarter 2023 Earnings Call

Lemonade Announces Extension of CAC Financing Agreement with General Catalyst

Business Wire

a year ago

Lemonade Announces Extension of CAC Financing Agreement with General Catalyst

EMPLOYERS® Named GHLA's Choice for Workers' Comp

Business Wire

a year ago

EMPLOYERS® Named GHLA's Choice for Workers' Comp

Data Analytics Stocks Q3 Recap: Benchmarking Domo (NASDAQ:DOMO)

StockStory

a year ago

Data Analytics Stocks Q3 Recap: Benchmarking Domo (NASDAQ:DOMO)

PALISADES ANNOUNCES NEW FOUND INTERCEPTS AT HONEYPOT ZONE AT QUEENSWAY PROJECT

CNW Group

a year ago

PALISADES ANNOUNCES NEW FOUND INTERCEPTS AT HONEYPOT ZONE AT QUEENSWAY PROJECT

Is Now An Opportune Moment To Examine Health Catalyst, Inc. (NASDAQ:HCAT)?

Simply Wall St.

a year ago

Is Now An Opportune Moment To Examine Health Catalyst, Inc. (NASDAQ:HCAT)?

Here's Why We Think Columbus McKinnon (NASDAQ:CMCO) Might Deserve Your Attention Today

Simply Wall St.

a year ago

Here's Why We Think Columbus McKinnon (NASDAQ:CMCO) Might Deserve Your Attention Today

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Zacks

a year ago

Amicus (FOLD) Issues Preliminary Revenue Results for FY23

Calliditas to present at JP Morgan Healthcare Conference

PR Newswire

a year ago

Calliditas to present at JP Morgan Healthcare Conference

SI-BONE Inc Director Davis Timothy E JR Sells 9,900 Shares

GuruFocus.com

a year ago

SI-BONE Inc Director Davis Timothy E JR Sells 9,900 Shares

Share on Social Networks: